ストックスクリーナーアプリを入手
1.43
5.92%
-0.09
アフターアワーズ：
1.39
-0.04
-2.80%
前日終値:
$1.52
開ける：
$1.53
24時間の取引高:
13.20M
Relative Volume:
0.98
時価総額：
$910.80M
収益：
$29.48M
当期純損益:
$-201.19M
株価収益率:
-4.4688
EPS:
-0.32
ネットキャッシュフロー:
$-216.50M
1週間 パフォーマンス:
-1.38%
1か月 パフォーマンス:
+3.62%
6か月 パフォーマンス:
-64.60%
1年 パフォーマンス:
-59.72%
1日の値動き範囲:
$1.39
$1.54
1週間の範囲:
$1.39
$1.60
52週間の値動き範囲:
$1.17
$5.34
Geron Corp Stock (GERN) Company Profile
名前
Geron Corp
セクター
電話
(650) 473-7700
住所
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
GERN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.43 | 949.01M | 29.48M | -201.19M | -216.50M | -0.32 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-08 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2025-02-27 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2025-02-26 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | 開始されました | H.C. Wainwright | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-09 | 開始されました | Leerink Partners | Outperform |
| 2024-04-30 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-04-29 | 開始されました | TD Cowen | Buy |
| 2024-03-15 | 繰り返されました | Needham | Buy |
| 2023-09-12 | アップグレード | Goldman | Neutral → Buy |
| 2023-03-28 | 開始されました | Goldman | Neutral |
| 2022-10-28 | 開始されました | Wedbush | Outperform |
| 2022-07-28 | 再開されました | B. Riley Securities | Buy |
| 2021-11-02 | 開始されました | Robert W. Baird | Outperform |
| 2021-02-18 | 再開されました | B. Riley Securities | Buy |
| 2020-08-03 | 開始されました | Stifel | Buy |
| 2019-11-19 | 再開されました | B. Riley FBR | Buy |
| 2019-09-03 | 開始されました | H.C. Wainwright | Buy |
| 2019-08-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-04-09 | アップグレード | Needham | Hold → Buy |
| 2019-01-31 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-10-02 | ダウングレード | B. Riley FBR | Buy → Neutral |
| 2018-07-05 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2016-09-13 | 繰り返されました | FBR & Co. | Outperform |
| 2016-09-13 | 繰り返されました | FBR Capital | Outperform |
| 2015-12-07 | 繰り返されました | Piper Jaffray | Overweight |
| 2015-04-21 | 開始されました | Oppenheimer | Outperform |
| 2014-06-12 | アップグレード | MLV & Co | Hold → Buy |
| 2014-03-12 | ダウングレード | MLV & Co | Buy → Hold |
| 2013-12-10 | 繰り返されました | MLV & Co | Buy |
| 2013-12-10 | アップグレード | Needham | Hold → Buy |
| 2013-11-08 | 繰り返されました | MLV & Co | Buy |
| 2013-10-16 | 開始されました | MLV & Co | Buy |
| 2012-08-30 | 開始されました | Stifel Nicolaus | Buy |
| 2012-06-28 | 開始されました | Needham | Hold |
すべてを表示
Geron Corp (GERN) 最新ニュース
Nuveen Asset Management LLC Purchases 14,657 Shares of Geron Co. (NASDAQ:GERN) - Defense World
Geron showcases RYTELO benefits at oncology meetings By Investing.com - Investing.com South Africa
Geron’s SWOT analysis: oncology firm’s stock faces growth hurdles By Investing.com - Investing.com South Africa
Geron showcases RYTELO benefits at oncology meetings - Investing.com
Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program - Yahoo Finance
Geron’s SWOT analysis: oncology firm’s stock faces growth hurdles - Investing.com
Geron Corp stockholders approve equity plan amendments By Investing.com - Investing.com India
Geron Corp stockholders approve equity plan amendments - Investing.com
BNP Paribas Financial Markets Decreases Stock Holdings in Geron Co. (NASDAQ:GERN) - Defense World
25,148 Shares in Geron Co. (NASDAQ:GERN) Purchased by Lazard Asset Management LLC - Defense World
Geron Co. (NASDAQ:GERN) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Bank of America Corp DE Boosts Stock Position in Geron Co. (NASDAQ:GERN) - Defense World
Ameriprise Financial Inc. Buys 247,018 Shares of Geron Co. (NASDAQ:GERN) - Defense World
Geron Grants $522K Worth of Stock Options and RSUs: New Employee Compensation Details Revealed - Stock Titan
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Stifel Financial Corp Increases Position in Geron Co. (NASDAQ:GERN) - Defense World
Geron Corp Stock (GERN): Demand Recovery on the Rise - Value The Markets
Northern Trust Corp Has $19.76 Million Stake in Geron Co. (NASDAQ:GERN) - Defense World
Why Geron Corporation (GERN) Is The Best Low Priced Biotech Stock to Buy Now - Insider Monkey
Geron Corporation Investors: Please contact the Portnoy Law - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron - Business Wire
GERN Investors are Reminded of an Opportunity to Lead Geron Corp - GuruFocus
10 Best Low Priced Biotech Stocks to Buy Now - Insider Monkey
GERN Investors are Reminded of an Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm - Benzinga
Geron outlines strategies to boost RYTELO adoption and anticipates Phase III myelofibrosis trial results in 2026 - MSN
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron LawsuitGERN - Stockhouse
Faruqi & Faruqi Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025GERN - GlobeNewswire
Research Analysts Set Expectations for Geron FY2028 Earnings - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 3D Systems Corporation - GlobeNewswire Inc.
Geron: Rytelo's Limited Adoption And Flat Demand Signal Troubled Outlook (Rating Downgrade) - Seeking Alpha
Lost Money on Geron Corporation (GERN)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Stockhouse
Geron slips as Scotiabank downgrades on sales challenges for blood cancer drug - MSN
Geron (GERN) Faces Downgrade Amid Rytelo Rollout Concerns - GuruFocus
Geron stock is downgraded at Scotiabank (GERN:NASDAQ) - Seeking Alpha
Geron (GERN) Price Target Reduced by Wedbush Amid Uptake Challen - GuruFocus
Geron (GERN) Experiences Notable Downgrade from Scotiabank | GER - GuruFocus
Geron Corporation (NASDAQ:GERN) Q1 2025 Earnings Call Transcript - Insider Monkey
Geron (GERN) Experiences Notable Downgrade from Scotiabank | GERN Stock News - GuruFocus
Geron (GERN) Faces Downgrade Amid Rytelo Launch Challenges | GERN Stock News - GuruFocus
Class Action Filed Against Geron Corporation (GERN) Seeking Recovery for InvestorsContact Levi & Korsinsky - Stockhouse
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Geron Corporation(GERN) Shareholders - PR Newswire
Geron Corp (GERN) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and Strategic ... - Yahoo Finance
Geron: Q1 Earnings Snapshot - New Haven Register
Geron Corp (GERN) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and Strategic Growth Initiatives - GuruFocus
MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Why Geron Stock Crept Higher Today - Barchart.com
Geron Corporation (GERN) Targets RYTELO Growth Amid Revenue Dip - GuruFocus
Geron Corp. Posts Narrower Loss In Q1 - Nasdaq
Earnings call transcript: Geron meets Q1 2025 EPS forecast, stock dips - Investing.com
Geron (GERN) Reports Q1 Revenue Below Expectations, Focuses on R - GuruFocus
Geron (GERN) Posts Narrower Q1 Loss Amid Revenue Surge - GuruFocus
Geron Corp (GERN) 財務データ
収益
当期純利益
現金流量
EPS
Geron Corp (GERN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Samuels Scott Alan | EVP, Chief Legal Officer |
Feb 27 '25 |
Buy |
1.61 |
15,000 |
24,150 |
26,682 |
| SCARLETT JOHN A | Chairman, President and CEO |
Feb 27 '25 |
Buy |
1.76 |
12,500 |
22,062 |
12,500 |
| Ziegler James | EVP, Chief Commercial Officer |
Feb 27 '25 |
Buy |
1.60 |
100,000 |
160,000 |
100,000 |
| GRETHLEIN ANDREW J | EVP, Chief Operating Officer |
Jul 08 '24 |
Option Exercise |
1.72 |
674,348 |
1,159,879 |
674,348 |
| GRETHLEIN ANDREW J | EVP, Chief Operating Officer |
Jul 08 '24 |
Sale |
4.56 |
674,348 |
3,073,004 |
0 |
| Feller Faye | EVP, Chief Medical Officer |
Jun 10 '24 |
Option Exercise |
1.19 |
287,900 |
341,693 |
155,400 |
| Feller Faye | EVP, Chief Medical Officer |
Jun 10 '24 |
Sale |
4.63 |
287,900 |
1,334,129 |
0 |
| Kapur Anil | EVP, Corp Strategy & CCO |
Jun 10 '24 |
Option Exercise |
1.06 |
421,875 |
447,188 |
421,875 |
| Kapur Anil | EVP, Corp Strategy & CCO |
Jun 10 '24 |
Sale |
4.64 |
421,875 |
1,959,609 |
0 |
| SCARLETT JOHN A | Chairman, President and CEO |
Jun 04 '24 |
Option Exercise |
2.54 |
600,000 |
1,524,000 |
600,000 |
6.29%
大文字化:
|
ボリューム (24 時間):